)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ortivus
Ortivus (ORTI) investor relations material
Ortivus Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary25 Aug, 2026
Executive summary
Net sales for April–June 2026 decreased by 2% year-over-year to SEK 19.3 million, while gross margin dropped to 37% from 51% due to increased hardware sales and replacements.
EBITDA improved to SEK -2.8 million from SEK -4.7 million, and net profit after tax was SEK -3.6 million, up from SEK -6.5 million in the prior year.
For January–June 2026, net sales rose 8% year-over-year to SEK 40.8 million, with a gross margin of 42% (down from 46%).
The company continues to invest in its MobiMed platform, expanding SaaS offerings and entering new markets such as Australia.
Financial highlights
April–June 2026 net sales: SEK 19.3 million (down 2% year-over-year); gross margin: 37% (down from 51%).
EBITDA: SEK -2.8 million (improved from SEK -4.7 million); net profit after tax: SEK -3.6 million (improved from SEK -6.5 million).
January–June 2026 net sales: SEK 40.8 million (up 8% year-over-year); gross margin: 42% (down from 46%).
Cash and cash equivalents at period end: SEK 6.7 million (up from SEK 1.6 million year-over-year).
Equity ratio improved to 24% from -26% year-over-year.
Outlook and guidance
Continued investment in MobiMed platform, with new SaaS applications and expansion into Australia and other English-speaking markets.
Transition to semi-annual financial reporting; next report will be the 2026 year-end report.
No formal forecasts provided; forward-looking statements subject to risks and uncertainties.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ortivus
- Net sales fell 18% but gross margin rose to 42%, with new UK contracts and ongoing digital investments.ORTI
Q1 2025 - Q2 2025 saw improved margins, positive adjusted EBITDA, and major contract wins, despite a project loss.ORTIQ2 2025
- Revenue up 18% year-over-year, gross margin at 47%, and EBITDA turned positive.ORTIQ1 2026
- Gross margin rose to 40% in 2025 despite lower sales and significant non-recurring costs.ORTIQ4 2025
- Sales and margins fell, but new capital and rising demand support a positive outlook.ORTIQ3 2025
- Net sales rose 17% in Q3 2024, with gross margin up to 47% and losses narrowing sharply.ORTIQ3 2024
- Q2 sales declined and losses widened, but new contracts and cost cuts set up H2 recovery.ORTIQ2 2024
- Q4 sales up, full-year loss deepened, but cash flow and new contracts signal growth potential.ORTIQ4 2024
Next Ortivus earnings date
Q4 202619 Feb, 2027
Ortivus
Next Ortivus earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ortivus AB is a Swedish medical technology company developing and commercializing solutions for healthcare industry. The Company's solutions are based on its proprietary technologies developed to improve the workflow efficiency in clinical laboratories, as well as reduce costs in organizations that provide diagnostic healthcare services.